{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/prescribing-information/nicorandil/","result":{"pageContext":{"chapter":{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil","depth":2,"htmlHeader":"<!-- begin field e4babee8-392d-4adb-992f-19fab59eb04d --><h2>Nicorandil</h2><!-- end field e4babee8-392d-4adb-992f-19fab59eb04d -->","summary":"","htmlStringContent":"<!-- begin item 0cf82872-76aa-49f2-b872-c9e259a6aa83 --><!-- end item 0cf82872-76aa-49f2-b872-c9e259a6aa83 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fbc0ef6c-8cc7-569a-b2c4-c44470a20e5c","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 41b9d2cd-df8d-4215-892b-a70300f5bbae --><h3>Dose</h3><!-- end field 41b9d2cd-df8d-4215-892b-a70300f5bbae -->","summary":"","htmlStringContent":"<!-- begin item 9662be35-79a4-4b2b-ae8f-a70300f5ba14 --><!-- begin field 603e61a7-aca6-4900-9919-a70300f5bbae --><ul><li>Initial dose — 10 mg twice daily, ideally in the morning and in the evening.<ul><li>A lower starting dose of 5 mg twice daily can be used in people who suffer from headaches. </li></ul></li><li>Maintenance dose — 10 to 20 mg twice daily, titrated up to 40 mg twice daily, if required and tolerated.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2015</a>]</p><!-- end field 603e61a7-aca6-4900-9919-a70300f5bbae --><!-- end item 9662be35-79a4-4b2b-ae8f-a70300f5ba14 -->","subChapters":[]},{"id":"23a79cb0-a5f0-555d-bafa-7033ac0f9804","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 6d88706d-16ef-4f65-811d-1c9cbd1de318 --><h3>Cautions and contraindications</h3><!-- end field 6d88706d-16ef-4f65-811d-1c9cbd1de318 -->","summary":"","htmlStringContent":"<!-- begin item 0151bef4-c7f9-4e81-b041-16f426639bac --><!-- begin field d3821211-caab-4dc7-a8e5-a9f2d1d2c9c2 --><ul><li><strong>Nicorandil is contraindicated in people with</strong>:<ul><li>Cardiogenic shock.</li><li>Severe hypotension.</li><li>Left ventricular failure with low filling pressure.</li><li>Hypovalaemia.</li><li>Acute pulmonary oedema.</li></ul></li><li><strong>Nicorandil should be used with caution in people with:</strong><ul><li>Acute myocardial infarction with acute left ventricular failure and low filling pressures.</li><li>Diverticular disease.</li><li>Hyperkalaemia.</li><li>Heart failure.</li><li>Glucose-6-phosphate dehydrogenase (G6PD) deficiency.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]</p><!-- end field d3821211-caab-4dc7-a8e5-a9f2d1d2c9c2 --><!-- end item 0151bef4-c7f9-4e81-b041-16f426639bac -->","subChapters":[]},{"id":"91a9a14f-eff3-5dca-99f0-23a57fdda438","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a287ff96-43a6-49aa-a298-19aab714969d --><h3>Adverse effects</h3><!-- end field a287ff96-43a6-49aa-a298-19aab714969d -->","summary":"","htmlStringContent":"<!-- begin item d2324d5d-f8ff-4d5b-9a52-0727156bbb7b --><!-- begin field ba6d9f9d-8a0d-4ef3-9e65-47850b3a5e0a --><p><strong>Adverse effects of nicorandil include</strong>: </p><ul><li>Headache (very common) — occurs in 22–48% of people taking nicorandil, and usually during the first 2 weeks of treatment. It is dose-related, and tends to diminish with continued use, although 10% of people stop using it as a result.</li><li>Other common adverse effects include: dizziness, heart rate increases, cutaneous vasodilation with flushing, vomiting, nausea, weakness. </li><li>Uncommon adverse effects include: hypotension, angio-oedema, and myalgia.</li><li><strong>Ulceration:</strong><ul><li>Gastrointestinal ulceration (including aphthous ulcers and anal ulceration) has been reported with nicorandil (rarely). This may progress to perforation, haemorrhage, fistula, or abscess. Almost two-thirds of reported gastrointestinal ulcers are serious.</li><li>Serious skin, mucosal, and eye ulceration (very rarely).<ul><li>Ulcers that result from nicorandil are usually refractory to treatment, and respond only to withdrawal of nicorandil — withdrawal should take place under the supervision of a cardiologist.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Micromedex, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">MHRA, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2015</a>]</p><!-- end field ba6d9f9d-8a0d-4ef3-9e65-47850b3a5e0a --><!-- end item d2324d5d-f8ff-4d5b-9a52-0727156bbb7b -->","subChapters":[]},{"id":"0ca96884-639d-55d4-9908-e0f7a51e9988","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e7b9ec9a-82d5-496b-8772-1bf937ed846c --><h3>Drug interactions</h3><!-- end field e7b9ec9a-82d5-496b-8772-1bf937ed846c -->","summary":"","htmlStringContent":"<!-- begin item a983c75d-da44-41a5-bc6d-02201d56e11d --><!-- begin field d79bceaf-fb57-4e8e-b5b9-387909c2e360 --><ul><li><strong>Phosphodiesterase inhibitors</strong> (such as sildenafil, tadalafil, vardenafil)— concomitant use with nicorandil is contraindicated, as it can cause potentially serious hypotension.</li><li><strong>Soluble guanylate cyclase stimulators </strong>(such as riociguat)<strong> </strong>— concomitant use with nicorandil is contraindicated, as it can lead to serious hypotension.</li><li><strong>Corticosteroids </strong>(such as prednisolone) — gastrointestinal ulceration has been reported in people concomitantly taking nicorandil with corticosteroids, and caution is advised if given concurrently.</li><li><strong>Antihypertensives</strong> — concomitant use with nicorandil may enhance the blood pressure lowering effect. Caution is advised. </li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — concomitant use with nicorandil, there is an increased risk of severe complications such as gastrointestinal ulceration, perforation and haemorrhage. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]</p><!-- end field d79bceaf-fb57-4e8e-b5b9-387909c2e360 --><!-- end item a983c75d-da44-41a5-bc6d-02201d56e11d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}